
News|Articles|April 30, 2025
Cancer Vaccines Begin to Take Center Stage With Investigators Anticipating an Even Brighter Future
Author(s)Kyle Doherty
Fact checked by: Caroline Seymour
Expert investigators discuss the current and future landscape of cancer vaccine development in various tumor types.
Advertisement
Advertisement
Vaccines are a major topic of interest in the world of cancer care, offering the promise of an effective treatment option in traditionally hard-to-manage tumor types that can potentially be personalized for individual patients. In order to further elucidate the current role of vaccines in the therapeutic paradigm of multiple tumor types and learn more about promising vaccines in development, OncLive® interviewed several investigators to gain their perspective on these exciting agents.
Related to this article

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

ASCO’s ctDNA guidelines support testing for genetic alterations in select scenarios but do not endorse it for residual disease or recurrence monitoring.

Updated ASCO Living Guideline recommendations expand frontline therapy for HER2-positive gastroesophageal cancer to include zanidatamab-based regimens.

Paul E. Oberstein, MD, discusses autogene cevumeran, a personalized mRNA vaccine, which is being evaluated for pancreatic ductal adenocarcinoma.

Following the RASolute 302 readout, ESMO now endorses daraxonrasib after chemotherapy progression in RAS-mutated metastatic pancreatic cancer.

UGN-103, a next-generation mitomycin formulation built on the ZUSDURI foundation, is supported by three-month CR and six-month DOR data from the phase 3 UTOPIA trial.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
Advertisement
Advertisement

